Get the Stockscreener App
5.57
0.30%
0.06
After Hours:
5.57
Unicycive Therapeutics Inc stock is traded at $5.57, with a volume of 513.89K.
It is up +0.30% in the last 24 hours and up +2.73% over the past month.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
See More
Previous Close:
$5.51
Open:
$5.5
24h Volume:
513.89K
Relative Volume:
0.35
Market Cap:
$155.29M
Revenue:
$675.00K
Net Income/Loss:
$-39.95M
P/E Ratio:
-2.7086
EPS:
-2.0564
Net Cash Flow:
$-28.67M
1W Performance:
+10.10%
1M Performance:
+2.73%
6M Performance:
-11.14%
1Y Performance:
+17.59%
1-Day Range:
$5.405
$5.61
1-Week Range:
$4.975
$5.65
52-Week Range:
$3.71
$8.74
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW
Compare UNCY vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
5.575 | 153.48M | 675.00K | -39.95M | -28.67M | -2.0564 |
VRTX
Vertex Pharmaceuticals Inc
|
515.43 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.92 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.25 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.31 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.63 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Guggenheim | Buy |
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
Noble Financial Has Positive Forecast for UNCY Q3 Earnings - MarketBeat
Research Analysts Set Expectations for UNCY Q3 Earnings - MarketBeat
UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time? - Stocktwits
Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to Hold at Wall Street Zen - MarketBeat
Nantahala Capital (UNCY) discloses 2.81M-share, 9.99% holding in Unicycive - Stock Titan
Unicycive Therapeutics (UNCY): Vivo Opportunity reports 9.99% beneficial ownership stake - Stock Titan
Noble Financial Has Pessimistic View of UNCY Q2 Earnings - MarketBeat
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - Benzinga
B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating - marketscreener.com
H.C. Wainwright Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Unicycive Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.5, Implies 550% Upside - TradingView
Unicycive Therapeutics (NASDAQ:UNCY) Announces Quarterly Earnings Results - MarketBeat
Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.7, Implies 554% Upside - TradingView
Unicycive Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Unicycive Therapeutics Q2 Results: EPS beats estimates by 82% - scanx.trade
Form 8K Unicycive Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Unicycive Reports Q2 2026 Results: $1.7M Net Loss, $61.4M Cash and Runway Into 2027 - TradingView
Unicycive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Unicycive Reports Q2 Loss As FDA Assigns OLC Facility Inspection - Moomoo
Unicycive Therapeutics shares rise after second-quarter loss beats forecasts - Yahoo Finance
Unicycive Therapeutics stock rises 2% on second quarter earnings beat By Investing.com - Investing.com South Africa
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Unicycive Therapeutics Reports FDA Facility Inspection Assigned for OLC Manufacturing Vendor, Plans NDA Resubmission After Successful Inspection - Quiver Quantitative
Unicycive Reports $61.4M in Cash and Securities as FDA Assigns Inspection - Stock Titan
Unicycive Therapeutics (UNCY) posts $14.5M H1 loss, raises $34M equity - Stock Titan
Unicycive Therapeutics, Inc. Q2 2026: Net income $(1.72M), EPS $(0.06) — 10-Q Summary - TradingView
Unicycive Therapeutics (UNCY) Earnings Date and Reports 2026 - MarketBeat
Unicycive: Solving Launch Data Challenges with Unlimited Access to Patient Data - Veeva
Unicycive Therapeutics Inc (UNCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Unicycive Therapeutics Inc (UNCY) Stock News Today - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeut - natlawreview.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Thursday - MarketBeat
BlackRock, Inc. Expands Stake in Unicycive Therapeutics Inc (UNC - GuruFocus
BlackRock (UNCY holder) reports 5.3% Unicycive Therapeutics stake in Schedule 13G - Stock Titan
Unicycive Therapeutics (UNCY) director granted 47,941 RSUs with staged vesting - Stock Titan
Unicycive Therapeutics Inc (UNCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Unicycive Therapeutics Inc (UNCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Unicycive Therapeutics Inc (UNCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Unicycive Therapeutics, Inc. Revenue Breakdown – NASDAQ:UNCY - TradingView
Unicycive Therapeutics Inc (UNCY) Balance Sheet - TradingKey
Unicycive Therapeutics Inc (UNCY) Cash Flow - TradingKey
UNCY|Unicycive Therapeutics Inc|Price:5.185|Chg%:-0.215 - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive The - The National Law Review
Unicycive Therapeutics Inc (UNCY) Income Statement - TradingKey
Unicycive Therapeutics: Two CRLs, One Fixable Problem (NASDAQ:UNCY) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bronstein, Gewirtz & Grossman, LLC (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire
Unicycive Therapeutics Inc (UNCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Unicycive Therapeutics Inc (UNCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):